Tag:

Xgeva

Latest Headlines

Latest Headlines

Top 15 Drug Launch Superstars

Herewith we bring you our Top 15 Drug Launch Superstars. Some of them will be obvious to anyone who follows the pharma business. They certainly were obvious to us. But choosing the rest was a challenge--one we weren't exactly expecting, based on previous experience. Read the full report >>

Amgen's Xgeva gets new approval, just not one it wants most

Amgen has gotten an FDA approval for an expanded use of its drug Xgeva, just not the one it covets most. The drug was approved Thursday for treatment of the rare giant cell tumor of the bone (GCTB).

Amgen's Xgeva wins NICE over with discount plan

The U.K.'s cost-effectiveness watchdogs have warmed up to Amgen's bone drug Xgeva. The company sweetened its discount offer, and that persuaded the National Institute for Health and Clinical Excellence to let Xgeva in.

NICE does an about-face, nixing cancer nod on Xgeva

The U.K.'s cost-effectiveness watchdog is having second thoughts about Amgen's new bone drug.

Amgen gets a no from the FDA on extended use of Xgeva

The FDA told Amgen no to an expanded use of its cancer treatment Xgeva, one of the company's most important drugs, saying the company could try again with more data.

FDA panel nixes new use for Amgen's Xgeva

The FDA's expert advisors didn't buy Amgen's ($AMGN) argument for earlier use of its bone drug Xgeva in prostate cancer patients. The idea: Treat advanced prostate cancer patients with...

Amgen's Xgeva faces FDA skepticism

The FDA isn't convinced that Amgen ($AMGN) needs another bone-metastasis indication for its new drug Xgeva. The drug is already approved to treat skeletal side effects in cancer patients, but Amgen

Amgen's Xgeva faces doubters on new indication

The FDA isn't convinced that Amgen ($AMGN) needs another bone-metastasis indication for its new drug Xgeva. The drug is already approved to treat skeletal side effects in cancer patients, but Amgen

Amgen's new meds beat estimates as anemia drugs slip

Amgen's ($AMGN) anemia drugs faltered again in the fourth quarter with sales declining 15% on Aranesp and 18% on Epogen. New bone drugs Xgeva and Prolia beat analyst estimates for their first full

Amgen aims for growth in bone drugs, overseas markets

Amgen's ($AMGN) incoming CEO has high hopes for this year. Now COO, Robert Bradway says he's looking for revenue growth in 2012, thanks in part to international expansion. Another driver: Sales of